Kuva raises Lisata deal price, pushes tender offer to June 1

By AI, Created 9:31 PM UTC, May 29, 2026, /AGP/ – Kuva Labs and Lisata Therapeutics amended their merger agreement on May 29, 2026, lifting the cash offer to $4.00 per share and adding a contingent value right tied to clinical milestones. Kuva now plans to begin the tender offer on June 1, after previously targeting May 29.

Why it matters: - The revised terms increase the upfront cash value for Lisata stockholders and add potential upside if key development milestones are reached. - The amendment also signals that Kuva still intends to move ahead with the acquisition, but on a slightly delayed timetable.

What happened: - Kuva Labs, Lisata Therapeutics and Kuva Acquisition amended their March 6, 2026 merger agreement on May 29, 2026. - The tender offer consideration was changed to $4.00 per Lisata share in cash, net to the seller, plus one contingent value right per share. - Kuva and Lisata extended the deadline for Kuva Acquisition to start the offer from May 29 to June 1, 2026. - Kuva said it intends to commence the offer on June 1, 2026.

The details: - The CVR gives holders the right to receive up to $3.00 per share in two cash payments. - The first payment is $1.25 per share if one of three milestones is reached for the Phase 2a proof-of-concept glioblastoma trial of LSTA1 added to standard of care temozolomide versus temozolomide and placebo. - The first milestone is met if the trial completes enrollment, reaches at least 90% of target enrollment, or is terminated by its sponsor for any reason. - The second payment is $1.75 per share if a New Drug Application for certepetide, formerly known as LSTA1 or CEND-1, is filed or formally accepted for review by a government authority. - If a milestone is not met, no payment is owed for that milestone. - The tender offer has not yet commenced. - Once commenced, Parent and Purchaser will file a Schedule TO with the SEC. - Lisata will file a Schedule 14D-9 recommendation statement with the SEC. - Lisata stockholders will receive the tender offer materials free of charge if the offer starts. - The documents will be available at Lisata investor relations and on the SEC’s website at www.sec.gov.

Between the lines: - The added CVR shifts part of the deal value from guaranteed cash to milestone-based consideration tied to clinical and regulatory progress. - The structure gives Kuva a way to bridge valuation differences while limiting guaranteed payout if the development program falls short. - The filing also includes extensive forward-looking risk disclosures, including the possibility that the offer is never launched or the milestone payments are never earned.

What’s next: - Kuva is expected to launch the tender offer on June 1, 2026, if it proceeds as planned. - The parties will then file the required SEC tender-offer and recommendation materials. - Deal completion will depend on tender response, closing conditions and regulatory and legal developments.

The bottom line: - Kuva has sweetened the Lisata bid, but a meaningful portion of the value now depends on whether Lisata’s cancer-drug milestones are achieved.